Prot #VX21‐522‐001: A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX‐522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

Project: Research project

Project Details

StatusActive
Effective start/end date10/31/23 → 10/31/26

Funding

  • Vertex Pharmaceuticals Incorporated (Prot #VX21-522-001)